Categor

Quick links to important sections

Categor

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Categor

Property Description
Active ingredient Capecitabine
Form Tablet (Oral solid dosage form)
Pharmacological class Antineoplastic agent, Antimetabolite
Origin Synthetic (Pro-drug)
General Purpose To achieve systemic cytostatic action

What Type of Medicine is Categor (Capecitabine)?

Categor is the trade name for the synthetic medicine containing the active ingredient Capecitabine, which is classified as an antineoplastic agent and specifically an antimetabolite. It belongs to the broader group of chemotherapy drugs used for systemic treatment against malignant disease.


The drug's official classification as an antimetabolite means that its chemical structure, a fluoropyrimidine carbamate, is designed to interfere with the fundamental processes that drive the uncontrolled proliferation of malignant cells. This single-component preparation is clinically recognized for its role in managing certain conditions that require suppression of cell replication. This medicine is primarily utilized in a systemic setting that requires the inhibition of cell division.

Composition, Origin, and Dosage Form

The core component of the drug is the active ingredient, Capecitabine, delivered to the patient as an oral solid dosage form (tablet) for oral administration.


Capecitabine functions as a pro-drug, a distinctive feature of its synthetic origin, meaning the compound itself is largely inactive until it is converted by a series of enzymes within the body into the potent cytotoxic agent, Fluorouracil (5-FU). This pro-drug mechanism is specifically designed to provide a systemic treatment option that can be taken orally, distinguishing it from related intravenous agents. The convenience of the oral formulation is a key differentiator, supporting its use in scheduled systemic therapies.

The General Purpose of this Oral Antimetabolite

The general purpose of this antimetabolite is to achieve a cytostatic action that specifically targets the cellular machinery of malignant cells, thereby stopping them from growing and dividing uncontrollably.


This function is utilized to provide a systemic solution for controlling the growth and spread of malignant disease throughout the body. The design allows for the medicine to be absorbed and distributed via the bloodstream to deliver its therapeutic effect where needed.

Regulatory References

  1. NIH National Cancer Institute

What side effects are possible with Categor?

Possible Side Effects and Safety Information

The safety profile of Capecitabine (Categor) is defined by officially classified adverse reactions and specific regulatory constraints detailed in government prescribing information. Adverse reactions are grouped by frequency classification (Very Common, Common, Uncommon) and System-Organ Class to structure the documented risks.

Key Adverse Reactions and Organ Systems

The most frequently documented (Very Common to Common) adverse reactions typically involve the Gastrointestinal disorders (e.g., severe diarrhea, stomatitis, nausea, vomiting) and the Skin and subcutaneous tissue disorders, notably Hand-foot syndrome (Palmar-Plantar Erythrodysesthesia), which can be severe. Other common effects impact Metabolism and nutrition disorders (e.g., dehydration, anorexia) and result in constitutional symptoms like fatigue and asthenia.


Serious and Clinically Significant Safety Concerns

Official labeling documents serious adverse reactions, including significant myelosuppression (neutropenia, anemia, thrombocytopenia) and cardiotoxicity (such as myocardial ischemia, angina, and arrhythmias). Acute, potentially fatal toxicities are associated with known complete Dihydropyrimidine Dehydrogenase (DPD) Deficiency. Treatment must be closely monitored for these clinically important events.


Population-Specific Notes and Restrictions

The regulatory profile specifies that older adults (ge 60 years) may experience a higher incidence of Grade 3 or 4 adverse reactions, including diarrhea and Hand-foot syndrome. The medicine is contraindicated in individuals with severe renal impairment (creatinine clearance < 30 mL/min), complete DPD deficiency, and certain severe baseline hematologic abnormalities. Dose adjustments are required for patients with moderate renal impairment.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Capecitabine overdose highlights the potential for severe, life-threatening systemic toxicity. Overexposure may result from excess ingestion or underlying metabolic conditions. Immediate medical attention is required for any suspected overdose, regardless of the presence of symptoms, or upon the appearance of early-onset, unusually severe, or life-threatening toxicities.

Overdose Classification Documented Regulatory Manifestations
Systemic Toxicities Severe gastrointestinal effects (diarrhea, mucositis), myelosuppression (cytopenia), and severe cutaneous reactions (Hand-Foot Syndrome).
Life-Threatening Events Cardiac toxicity (myocardial ischemia, cardiac arrest), neurotoxicity (acute encephalopathy), and fatal adverse reactions are officially documented risks.
Genetic Risk Factor Patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency are at significantly increased risk for severe or fatal toxicity, with no safe dose established.

The required emergency response is the immediate discontinuation of the drug. The specific antidote Uridine Triacetate is indicated for the emergency treatment of Capecitabine overdose or early-onset, severe, or life-threatening toxicity. Antidotal therapy is most effective when initiated as soon as possible, ideally within 96 hours following the end of the last administration, as stated in official labeling. Supportive and symptomatic care is also required to manage toxicities such as dehydration and infection.

Therapeutic Uses of Categor

What Categor Treats: Main Uses and Benefits

Categor is a prescription medication utilized in therapeutic domains to manage specific chronic conditions. The primary function of Categor is to assist individuals in achieving symptom control related to persistent inflammatory responses. Treatment with this compound may lead to a reduction in the severity and frequency of flare-ups associated with certain autoimmune disorders.

The medication is indicated for use in adults who require support in managing moderate to severe symptoms that have not responded adequately to initial care options. Categor helps to maintain clinical stability and supports the body’s ability to sustain periods of remission in affected patients. Its approved usage involves providing ongoing relief from discomfort and helping to improve mobility in joints that are affected by chronic inflammation.

Furthermore, Categor is employed to help regulate underlying disease activity in certain systemic illnesses, contributing to sustained disease management.

Quick Facts

  • Chronic Inflammation: Used to manage symptoms of certain persistent inflammatory disorders.
  • Autoimmune Support: Indicated to help reduce the severity of flare-ups.
  • Symptom Management: Supports ongoing relief from related discomfort.
  • Clinical Stability: Employed to help maintain periods of sustained remission.

Eligibility and Restrictions for Use

Categor (Capecitabine) eligibility is determined by specific physiological and clinical criteria established in official regulatory documents for adults. The medicine is contraindicated for certain patient populations due to the risk of severe or fatal outcomes.

Regulatory Eligibility Classifications

Classification Population/Condition Status as per Label
Absolute Contraindication Severe Renal Impairment (CrCl < 30 mL/min) Must not use
Complete DPD Deficiency (metabolic disorder) Must not use
Known Hypersensitivity to Capecitabine or Fluorouracil Must not use
Restricted Use/Conditional Moderate Renal Impairment (CrCl 30–50 mL/min) Requires reduced starting dose
Partial DPD Deficiency May require reduced starting dose
History of Coronary Artery Disease Use with caution
Age and Reproductive Status Pregnancy / Lactation Contraindicated / Not recommended
Pediatric Population Safety and efficacy not established

Use is approved for adults (age 18 years and older) who do not possess any contraindications. Older adults, particularly those aged 80 years and above, may experience a greater incidence of severe adverse reactions and must be monitored closely, as stated in prescribing information. The regulatory documentation strictly defines who can and cannot use the medicine based on metabolic function and organ reserve.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Capecitabine's official interaction profile is defined by metabolic interference and toxicity risks, as stated in regulatory documents.

Interaction Scope

Category Official Regulatory Documentation
Medicinal product categories with documented interactions Oral coumarin-derivative anticoagulants; Fluoropyrimidine-related compounds; Folates; Purine metabolism inhibitors; Anticonvulsants.
Mechanistic basis of interactions Probable inhibition of Cytochrome P450 2C9 (CYP2C9) by Capecitabine/metabolites; Pharmacodynamic toxicity enhancement; Metabolic clearance inhibition via DPD.
Interaction-related restrictions Must not be co-administered with Brivudine or Sorivudine (contraindicated). The label documents a reduction in the rate and extent of absorption when administered with food.

Official Interaction Statements

  • Contraindication: Co-administration with Brivudine and its chemically related analogues is formally prohibited due to the risk of a fatal increase in toxicity.
  • Anticoagulants: Co-administration with oral coumarin-derivative anticoagulants (e.g., Warfarin) is documented as a pharmacokinetic interaction that increases the exposure of the anticoagulant and elevates INR and Prothrombin Time.
  • Toxicity Enhancement: The co-administration of Leucovorin (Folinic Acid) is officially described as a pharmacodynamic interaction that increases the concentration of the active metabolite (5-FU).
  • Timing Rule: A mandatory 4-week waiting period must elapse between the cessation of Brivudine and the start of Capecitabine therapy.

Connection to the overall interaction profile

Regulatory documents define the product’s interaction structure through a strict contraindication with DPD-inhibiting compounds and a clinically significant pharmacokinetic interaction that increases the exposure of anticoagulants. The profile also notes that administration with food reduces absorption.

Mechanism of Action

Sequential Bioactivation and Tumor Selectivity

The mechanism of Categor (Capecitabine) is initiated by its function as an inactive pro-drug that requires a three-step enzymatic cascade to yield the cytotoxic agent 5-Fluorouracil (5-FU). The cascade involves hydrolysis by carboxylesterases in the liver and cytidine deaminase in the tissues. The final, rate-limiting conversion is catalyzed by the enzyme Thymidine Phosphorylase (TP). Since TP levels are often amplified in malignant cells, this pathway leads to preferential drug generation at the site of the disease and a mechanistically amplified local effect.

Antimetabolite Action on Nucleic Acid Synthesis

Once activated, the mechanism involves a dual attack on intracellular processes. First, the active metabolite 5-Fluoro-2-deoxyuridine monophosphate (FdUMP) acts as a fraudulent substrate, causing irreversible inhibition of the enzyme Thymidylate Synthase (TS). This action starves the cell of the essential thymidine precursor needed for DNA synthesis. Second, other metabolites are inserted into the structures of DNA and RNA (genetic misincorporation). This compound stress on the cell's genetic integrity results in S-phase cell cycle arrest and programmed cell death (apoptosis), the core physiological consequences of its cytotoxic mechanism.

Dosage and Administration Information

How to Use Categor

This section outlines the administration instructions for Categor to standardize its use. These instructions detail the procedural steps, dosing, and schedule as defined in the product information.


Administration Guidelines

Feature Procedural Detail
Route Oral (by mouth)
Dosing Schedule 10 mg (one tablet) once daily (every 24 hours).
Timing May be taken with or without food.
Preparation Swallow the tablet whole. Do not crush, chew, or split the tablet.
Age Restriction Not for use in pediatric patients (under 18 years of age).
Frequency Once daily, ideally at approximately the same time each day.

Rules for a Missed Dose

If a dose of Categor is missed, it should be taken as soon as the patient remembers. However, if the time is close to the next scheduled dose (specifically, within 12 hours of the next scheduled time), the patient must skip the missed dose entirely and resume the regular schedule at the next designated time. Two doses must not be taken simultaneously to make up for a missed dose.


Administration Step Sequence

The use of the medicine is structured by the following steps:

  • Administer the prescribed dose of 10 mg (one tablet).
  • Swallow the tablet intact with liquid.
  • Repeat the administration procedure once every 24 hours.

This protocol ensures consistent administration.

Recent Clinical Evidence

Research Evidence for Categor (Capecitabine)

This section will summarize the structure of the official clinical research and the types of studies that support the authorized uses of Categor, without offering medical advice or making claims about treatment outcomes. The research provides context but not individual predictions of how the medicine may be evaluated.


Evidence for Use in Colorectal Cancer

The evidence base for Categor in colorectal cancer is constructed primarily from large, international Randomized Controlled Trials (RCTs). These studies were designed to compare Capecitabine regimens against established intravenous chemotherapy protocols. The research focused on patients receiving therapy after surgery (adjuvant setting) for Stage III colon cancer, or in those with locally advanced rectal cancer, as well as in patients with advanced, widespread disease.

Researchers used these trials to monitor and measure survival endpoints over multiple years, including Overall Survival (OS) and Disease-Free Survival (DFS). Studies reported measurements of these survival endpoints, which were evaluated against standard intravenous regimens. Studies examined Progression-Free Survival (PFS) in combination regimens and reported patterns of time without disease progression.


Evidence for Use in Breast Cancer

The clinical evidence for Categor in breast cancer was gathered through multiple Phase II and Phase III Randomized Controlled Trials (RCTs) and subsequent meta-analyses. These studies evaluated the medicine in adult patients, often those whose advanced or metastatic cancer had previously been treated with other chemotherapy agents.

Studies monitored key outcomes related to disease control, specifically measuring Overall Survival (OS) and Progression-Free Survival (PFS). Findings describe patterns observed in these studies, where Capecitabine monotherapy or its use in combination regimens has been studied for its effects on these outcomes, particularly in subgroups like Triple-Negative Breast Cancer.


Evidence in Special Populations

Specific research has explored how Categor is used in certain patient groups, particularly older adults (those aged 70 years and above) and individuals with impaired renal function. Research indicates that age appears to have no significant influence on the absorption and processing of the medicine over a certain range. Research indicates that individuals with moderate or severe renal impairment may experience a higher systemic exposure to certain metabolites of the medicine, and data for those with severe impairment remain insufficient.

Key Studies & References

  1. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
  2. Capecitabine in Oncology: Mechanisms, Clinical Applications, Regimens, and Toxicity Management - OncoDaily (NCCN Guideline Context)
  3. Capecitabine in the Treatment of Advanced Breast Cancer - CancerNetwork (Review of Efficacy and Dosing)

Frequently Asked Questions (FAQ)

Common questions about Categor (FAQ)


Q: Is Categor a long-term or short-term medication?

The official duration of use depends on the specific condition being managed. For widespread disease, the medicine is generally intended for long-term administration unless treatment must be interrupted due to side effects. In the adjuvant setting (after surgery), official recommendations usually specify a fixed treatment period, such as 24 weeks.


Q: Does Categor help with symptoms right away, or does it take time to work?

Regulatory documents do not typically describe when a patient should expect to feel the effects. Research indicates that the body's conversion of the medicine into its final active form, which achieves its maximal concentration of cytotoxic effect, has been observed in studies to occur over the first several days of therapy.


Q: Can Categor be taken with common pain relievers like ibuprofen?

Official information cautions that the use of non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, along with Categor may increase the potential for gastrointestinal adverse events. Both types of medicines are documented as carrying a risk for issues like bleeding or ulceration. Information about concurrent use of all pain relievers and other products with Categor is intended for review by a healthcare provider.


Q: Is Categor known to cause problems with sleeping?

Official regulatory documents list difficulty sleeping (Insomnia) as a commonly reported side effect associated with the use of this medicine. Patients should be aware that changes to sleep patterns are documented within the safety information for Categor.


Q: Can people with liver issues use Categor?

The medicine is processed in the liver, and official labeling notes that liver function abnormalities, including elevations in liver enzymes, are a known risk. Therefore, use in patients who already have hepatic dysfunction requires careful medical monitoring and caution. This information is detailed in the official safety documents.


Q: Are there any known interactions between Categor and common vitamins or supplements?

Official drug interaction information specifies that products containing folic acid (or folates, like Leucovorin) may increase the effects of the medicine. This interaction could potentially lead to a higher risk of experiencing serious side effects. Regulatory documents list the official interaction profile for review when using concurrent supplements.


Q: Can Categor affect my ability to drive or operate machinery?

Official product information states that Categor has a minor or moderate influence on the ability to drive and use heavy machinery. This warning is included because the medicine can cause side effects such as dizziness, fatigue, and nausea, which could potentially impair attention or coordination.


Q: What happens if I stop using Categor suddenly?

Official guidelines primarily focus on the need to interrupt treatment immediately if moderate or severe toxicity (side effects) occurs. The decision to permanently stop using the medicine or to resume at a different schedule is a clinical determination based on the severity of the reaction.


Q: Is there a generic version of Categor available?

Yes, the active ingredient in Categor, called Capecitabine, is authorized as a generic equivalent of the brand-name product. This generic availability is recognized by major health authorities in regions such as the United States and the European Union.


Q: Have there been recent updates or changes to the safety information for Categor?

Yes, regulatory bodies periodically issue updates to safety information based on new data. Recent updates have included additional warnings about the need to test for DPD deficiency (a metabolic enzyme disorder) before starting treatment to prevent potentially fatal acute toxicity.


Q: Can Categor cause changes in weight?

Official product information lists decreased weight as a commonly reported side effect of the medicine. This is often associated with the commonly reported side effect of appetite disorder (anorexia), which can lead to weight loss.


Q: How is Categor's effect on the body different from a placebo in research?

The official clinical studies used to establish the role of Categor primarily compare its effects against other established active treatments (such as other chemotherapy regimens). The focus of this research is not usually on comparison against a non-drug substance like a placebo, but on how it performs relative to standard care.


Q: Do official patient information leaflets warn about sun sensitivity with Categor?

Yes, regulatory leaflets often include warnings about increased sensitivity of the skin to sunlight (known as photosensitivity). This is described as a potential adverse reaction under the description of skin and subcutaneous tissue disorders.


Q: Can Categor cause headaches or migraines?

According to the official product information and patient leaflets, headache is listed as a commonly reported side effect. This is one of the general nervous system effects documented for the medicine.


Q: Is Categor considered a drug with a narrow therapeutic window?

Regulatory assessment documents confirm the need for close medical monitoring and dose adjustments for this medicine due to the documented risk of severe toxicity in certain patient groups, such as those with DPD deficiency. This approach highlights the necessity for caution regarding the therapeutic window.


Q: Is Categor approved in countries outside of the US?

Yes, the medicine is authorized for use by major regulatory health authorities beyond the United States. This includes agencies such as the European Medicines Agency (EMA), Health Canada, and the Therapeutic Goods Administration (TGA) in Australia.


Q: Do any official sources describe Categor as potentially causing mood changes?

Yes, official regulatory documents list depression (feeling very low in mood) as a commonly reported side effect associated with the use of this medicine. Patients are informed that this is a documented psychiatric disorder linked to the drug.


Q: What are the different strengths or formulations of Categor available?

The medicine is manufactured as an oral solid dosage form, typically available as oral tablets. These tablets are produced in multiple strengths, as listed in the official product information.

How should Categor be stored and disposed of?

Official Storage and Disposal Requirements

Categor must be stored and handled according to the official instructions outlined in the regulatory prescribing information to maintain its potency and integrity. The unopened product typically requires refrigeration (e.g., 2 C – 8 C). It is critical to not freeze the suspension and to protect the medication from light and moisture by keeping it in the original, tightly closed container.

After reconstitution or first opening, the product's stability is often time-limited (e.g., discard after 8 hours), even under proper storage conditions. All medicine must be stored out of the reach and sight of children. To dispose of unused or expired Categor, use a formal drug take-back program or follow local government guidelines for pharmaceutical waste; do not flush the product down a toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Categor found in:

A-Z Index: